ISTH/LinkedIn
Sep 8, 2026, 07:02
Emerging Therapies in Thrombosis – Factor XI/XIa Inhibitor Trials – ISTH
International Society on Thrombosis and Haemostasis (ISTH) shared a post on LinkedIn:
“From the coagulation cascade to the latest clinical trials, take a closer look at the evolving science of Factor XI and Factor XIa inhibition.
In this on-demand session, Dr. Weitz provides a concise overview of FXI/FXIa inhibitors and compares some of the leading investigational therapies currently under evaluation.
See the evidence come to life through animated charts highlighting recent clinical data, study findings and the potential implications for anticoagulant therapy.
What could this emerging therapeutic approach mean for clinical practice?”
Other posts featuring ISTH on Hemostasis Today.
-
Oct 23, 2026, 16:05Platelet Secretion Defects and Their Role in the Diagnosis of Bleeding Disorders
-
Oct 23, 2026, 16:00Hemophilia Alliance team in New Orleans at the ATHN Data Summit
-
Oct 23, 2026, 15:49Brian Sapp: Why Exact Calf Vein Naming Is Critical for DVT Diagnosis?
-
Oct 23, 2026, 15:33Smitirupa Mishra: A Systematic Approach to Bone Marrow Examination
-
Oct 23, 2026, 15:29José Antonio García Erce: Preoperative Anemia Emerges as a Modifiable Surgical Risk in New POWER Study
-
Oct 23, 2026, 15:13Reza Shojaei: Manufactured Red Blood Cells vs Blood Donation
-
Oct 23, 2026, 14:29Jean Jacques Kiladjian: International Scientific Exchange at IHCAMS in Tianjin
-
Oct 23, 2026, 14:11Aravind Palraj: The Prolonged aPTT Puzzle in SLE
-
Oct 23, 2026, 13:56Chokri Ben Lamine: The Evolving Treatment Landscape of Persistent and Chronic ITP